Patents by Inventor Amir AMERI

Amir AMERI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Panel comprising Borrelia MHC multimers
    Publication number: 20250382335
    Abstract: Disclosed herein is a panel comprising one or more MHC multimers; and a panel comprising one or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers; wherein said MHC multimers comprise an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; as well as uses thereof in the detection of Borrelia-specific T cells and the diagnosis, treatment and monitoring of Borrelia disease in an individual.
    Type: Application
    Filed: February 24, 2025
    Publication date: December 18, 2025
    Inventors: Liselotte BRIX, Kivin JACOBSEN, Amir AMERI
  • Panel comprising MHC multimers
    Patent number: 12258373
    Abstract: Disclosed herein is a panel comprising one or more MHC multimers; and a panel comprising one or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers; wherein said MHC multimers comprise an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; as well as uses thereof in the detection of Borrelia-specific T cells and the diagnosis, treatment and monitoring of Borrelia disease in an individual.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: March 25, 2025
    Assignee: Immudex ApS
    Inventors: Liselotte Brix, Kivin Jacobsen, Amir Ameri
  • Panel comprising Borrelia MHC multimers
    Publication number: 20220064226
    Abstract: Disclosed herein is a panel comprising one or more MHC multimers; and a panel comprising one or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers; wherein said MHC multimers comprise an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; as well as uses thereof in the detection of Borrelia-specific T cells and the diagnosis, treatment and monitoring of Borrelia disease in an individual.
    Type: Application
    Filed: December 17, 2019
    Publication date: March 3, 2022
    Inventors: Liselotte BRIX, Kivin JACOBSEN, Amir AMERI